Brazil Launches Two-Year Semaglutide Pilot for 250 SUS Patients

Overview

• The Ministry of Health began the pilot at Grupo Hospitalar Conceição with the first patient dosed on Friday, June 26, 2026, and will enroll 250 public‑system patients over a two‑year protocol.
• Participants must have an obesity diagnosis for at least 12 months, documented failure of structured diet and exercise, ongoing care at GHC, and the ability to self‑inject or have a caregiver assist.
• The trial will measure percent weight loss, changes in quality of life, clinical exam results, postoperative conditions and the direct costs of care to assess clinical benefit and budget impact.
• Funding is routed through the UFRGS support foundation (FAURGS) from contributions by Novo Nordisk, a fact that links industry support to government evidence‑gathering and raises questions about independence and scale-up.
• The pilot responds to earlier advice from Conitec against SUS incorporation over an estimated R$8 billion annual cost and comes as semaglutide products expand in Brazil’s private market and regulatory approvals increase.